The April 1 2014 issue of the Journal of Commercial Biotechnology has just been published, and features the following papers:
Building biotechnology in India – Drugs are not the answer
Yali Friedman
I have had the pleasure of participating in national forums on biotechnology development in diverse countries. A common theme I see is that emerging economies wish to develop ‘a biotechnology industry like the United States.’ I generally temper these ambitions by explaining that the United States does not have a biotechnology industry per se, but rather a handful of states have very strong biotechnology concentrations and many other states are still trying to build their domestic biotechnology industries…
Full details at the Journal of Commercial Biotechnology
Fostering technology transfer in industrial biotechnology by academic spin-offs
Gunter Festel, Philipp Rittershaus
Industrial biotechnology is the commercial application of biotechnology using cells or components of cells, like enzymes, for industrial production processes including consumer goods, bioenergy and biomaterials…
Full details at the Journal of Commercial Biotechnology
Pharmaceutical R&D Productivity: The Role of Alliance
Sarah Kruse, Mark Slomiany, Rema Bitar, Sarah Jeffers, Mahmud Hassan
In recent years, the major research-intensive biopharmaceutical companies (big pharma) have come face to face with a perfect storm of eroding profit margins from blockbuster expiration and generic competition coupled with growing R&D expenses and declining advances in truly novel therapeutics…
Full details at the Journal of Commercial Biotechnology
Deciding between biobetter versus biosimilar development options based on net present value calculations
Kerstin Marie Bode-Greuel, Klaus Nickisch
AbstractThe growing share of biopharmaceuticals is paralleled by an increasing interest in biogenerics, as blockbuster biologics are approaching their patent expiries. Companies need to make decisions whether to invest in biosimilars or in biobetters with enhanced properties, the latter enabling favorable differentiation vis-à-vis the original product on the one hand and biosimilars on the other hand…
Full details at the Journal of Commercial Biotechnology
Market Orientation, Alliance Orientation, and Business Performance in the Biotechnology Industry
Grant Alexander Wilson, Jason Perepelkin, David Di Zhang, Marc-Antoine Vachon
The purpose of this study was to test the unexplored relationship between market orientation (MO), alliance orientation (AO), and business performance (PERF) in the medical/healthcare subsector of the Canadian biotechnology industry. The study surveyed Canadian biotechnology executives via mail and web-based questionnaires…
Full details at the Journal of Commercial Biotechnology
Bioentrepreneurship Education and Training Trends
Arlen Meyers
Biomedical and health entrepreneurship continues to expand around the world. Driven by global pressures to optimize the allocation of scarce resources, life science bioentrepreneurs are creating innovative products, platforms, service and systems that deliver more value…
Full details at the Journal of Commercial Biotechnology
Where is the eBay for Intellectual Property?
Matthew B Klusas, Raymond H. Cypess, Seth Rosenfield, Adam Gerstein
This paper is an examination of the economics, organizational dynamics and structural factors inhibiting an electronic market for intellectual property. Several intermediaries exist to facilitate the transition of intellectual property (IP) from sellers to buyers. Over the past 20 years, a number of companies attempted to create an online “eBay for IP…
Full details at the Journal of Commercial Biotechnology
Biotech IPOs Steam Ahead in 2014
G. Steven Burrill
If you walk into most private biotech company boardrooms today, it is likely that you will hear a discussion about whether to go public. Companies at every stage of development are either getting ready to file for an initial public offering or thinking about it. Although the slowdown in new issues at the end of 2013 gave observers pause that the robust biotech IPO market of 2013 might slow down in 2014, the reality has been just the opposite…
Full details at the Journal of Commercial Biotechnology
Considerations for Start-Up Biotech Company Valuation
Walter Bratic, Justin R Blok, Megan M Gostola
The prospect of government regulation, product liability lawsuits, and customer reliance on third-party payers contribute to the complexity of valuing biotech start-ups. In addition, the inherent complexity of biologic drug manufacturing and storage creates secondary risks that must be considered in a valuation…
Full details at the Journal of Commercial Biotechnology
Canadian Venture Capital – Unlocking the Funding Challenge
Christopher H. Jones
Canada plays a significant role in the global advancement of scientific discoveries and their translation into commercial opportunities, but is viewed as not fully realizing its commercial potential. A significant problem has been a lack of sufficient venture capital to take early-stage companies to the next level…
Full details at the Journal of Commercial Biotechnology
New Books
Yali Friedman
New books from the publisher of the Journal of CommercialBiotechnology
Full details at the Journal of Commercial Biotechnology